Skip to main content
TipRanks
Go Ultimate75% OFF

Kilitch Drugs (India) Limited (KILITCH) AI Stock Analysis

0 Followers
IN:KILITCH

Kilitch Drugs (India) Limited

(NSE:KILITCH)

Select Model
Rating:57Neutral
Price Target:INR 211.00â–¼(-2.04% Downside)
Action:reiterated
Date:10/22/26

The score is primarily constrained by weak cash generation—free cash flow has been persistently negative and deteriorated sharply in 2026, raising funding risk despite revenue growth and decent accounting profitability. Technicals are mixed with weak near-term momentum, while valuation appears mid-range based on the P/E provided.

Positive Factors
Revenue GrowthRevenue has expanded substantially over several years, indicating that the company is scaling its pharmaceutical formulation business across domestic and export markets. Continued growth provides a broader operating base, supports investment in niche products, and can strengthen earnings capacity if execution remains consistent.
Negative Factors
Persistent Negative Free Cash FlowPersistent negative free cash flow, culminating in a sharp deterioration in 2026, indicates that accounting profits are not translating into surplus cash. If this continues, the company may need more borrowing or other funding to support investment, increasing financial dependence and limiting capital-allocation flexibility.

Kilitch Drugs (India) Limited (KILITCH) vs. iShares MSCI India ETF (INDA)

-40%-20%0%20%40%60%IN:KILITCH+21.30%INDA-5.86%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 7.52B
Dividend Yield
―
Average Volume (3M)
6,370
Price to Earnings (P/E)
30.9
Beta (1Y)
0.63
Revenue Growth
13.87%
EPS Growth
-17.80%
Country
India
Employees
236
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Kilitch Drugs (India) Limited Business Overview & Revenue Model

Company Description

Kilitch Drugs (India) Limited, established in 1978 and based in Mumbai, operates a comprehensive pharmaceutical enterprise involved in the development and distribution of a wide array of medicinal and related products, both within India and for expor...

How the Company Makes Money

Kilitch Drugs (India) Limited primarily makes money by selling pharmaceutical finished dosage formulations (i.e., manufactured drug products) to customers in India and in international markets. Its revenue model is centered on: (1) Branded and/or gen...

Kilitch Drugs (India) Limited Financial Statement Overview

Summary

Strong multi-year revenue growth and improved profitability support the score, and leverage remains manageable. However, persistently negative free cash flow (sharply worse in 2026) and weaker cash conversion versus earnings, alongside rising debt, materially increase funding risk and pull the score down.

Income Statement

74Positive

Balance Sheet

71Positive

Cash Flow

38Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue2.39B2.35B1.98B1.54B1.40B1.14B
Gross Profit927.81M914.13M937.39M731.38M624.64M337.44M
EBITDA384.05M478.38M426.26M287.43M206.50M134.13M
Net Income240.91M301.66M267.01M146.01M104.48M73.67M
Balance Sheet
Total Assets4.64B4.58B3.13B2.40B2.20B2.10B
Cash, Cash Equivalents and Short-Term Investments577.35M687.39M593.98M690.19M591.77M572.43M
Total Debt966.43M887.09M494.24M316.46M221.94M204.32M
Total Liabilities1.80B1.81B1.12B643.88M689.41M695.55M
Stockholders Equity2.89B2.80B2.02B1.76B1.52B1.39B
Cash Flow
Free Cash Flow0-805.64M-293.31M-65.97M-12.26M-24.19M
Operating Cash Flow0189.43M175.42M-1.46M25.86M57.83M
Investing Cash Flow0-1.01B-399.47M-95.45M79.15M-152.50M
Financing Cash Flow0880.13M132.43M88.07M-7.16M70.28M

Kilitch Drugs (India) Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price215.40

Price Trends

50DMA208.82Positive
100DMA195.75Positive
200DMA178.51Positive

Market Momentum

MACD-2.97Positive
RSI53.89Neutral
STOCH55.23Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KILITCH, the sentiment is Positive. The current price of 215.40 is above the 20-day moving average (MA) of 208.10, above the 50-day MA of 208.82, and above the 200-day MA of 178.51, indicating a bullish trend. The MACD of -2.97 indicates Positive momentum. The RSI at 53.89 is Neutral, neither overbought nor oversold. The STOCH value of 55.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:KILITCH.

Kilitch Drugs (India) Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:KILITCH against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:ZIMLABIN:ZIMLAB60NeutralINR 7.60B263.30――13.14%-60.77%
IN:KILITCHIN:KILITCH57NeutralINR 7.53B30.88――13.87%-17.80%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:ALBERTDAVDIN:ALBERTDAVD54NeutralINR 4.48B15.52―0.63%19.69%―
IN:VALIANTLABIN:VALIANTLAB49NeutralINR 5.72B35.15――102.37%176.45%
IN:MEDICAMEQIN:MEDICAMEQ48NeutralINR 3.83B35.44―0.36%27.47%6.56%
IN:NECLIFEIN:NECLIFE47NeutralINR 2.08B-0.93――-99.85%78.93%

* General Sector Average

Performance Comparison

0%50%100%IN:KILITCHIN:ALBERTDAVDIN:MEDICAMEQIN:NECLIFEIN:VALIANTLABIN:ZIMLABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:KILITCH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:KILITCHKilitch Drugs (India) Limited215.4036.0520.10%
IN:ALBERTDAVDAlbert David Ltd785.00-21.09-2.62%
IN:MEDICAMEQMedicamen Biotech Limited282.70-113.26-28.60%
IN:NECLIFENectar Lifesciences Ltd.10.73-3.91-26.71%
IN:VALIANTLABValiant Laboratories Ltd.105.3525.5432.00%
IN:ZIMLABZim Laboratories Ltd.141.7068.7494.22%

Kilitch Drugs (India) Limited Corporate Events

Kilitch Drugs conducts fully virtual 34th AGM, highlights performance and governance

Aug 27, 2026

Kilitch Drugs (India) Limited held its 34th Annual General Meeting on August 27, 2026, conducted entirely via video conferencing in line with Companies Act and regulatory guidelines. The virtual AGM, attended by the full board, key management, statut...

Kilitch Drugs Files SEBI-Compliant Monitoring Report for June Quarter

Aug 18, 2026

Kilitch Drugs (India) Limited has submitted a monitoring agency report for the quarter ended June 30, 2026 to BSE and NSE, in line with disclosure requirements under SEBI’s listing and capital issue regulations. The report, prepared by Infomerics Val...

Kilitch Drugs Publishes Quarterly Results in Marathi and English Dailies

Aug 18, 2026

Kilitch Drugs (India) Limited has reported that extracts of its financial results for the quarter ended 30 June 2026 have been published in both Marathi and English newspapers. The publication, dated 15 August 2026, fulfills the company’s regulatory...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 22, 2026